2020-04-22 07:32:40 MYOV Myovant Sciences
04/22/20 04/2207:32 04/22/2007:32 | Myovant Sciences says co-primary endpoints met in Phase 3 SPIRIT 2 studyMyovant Sciences announced that SPIRIT 2, the first of two Phase 3 studies of once-daily relugolix combination therapy in women with pain associated with endometriosis, met its co-primary efficacy endpoints and six key secondary endpoints. In addition, relugolix combination therapy was generally well-tolerated including minimal bone mineral density loss over 24 weeks. Myovant also announced that, in a separate clinical study, relugolix combination therapy achieved 100% ovulation inhibition in 67 healthy women with no women ovulating during the 84-day treatment period, as evaluated by the Hoogland-Skouby assessment scale. Furthermore, 100% of women resumed ovulation or menses upon discontinuation of treatment with an average time to ovulation of 23.5 days. In the co-primary endpoint analysis of SPIRIT 2, 75.2% of women receiving once-daily relugolix combination therapy achieved a clinically-meaningful reduction in dysmenorrhea versus 30.4% of women in the placebo group. For non-menstrual pelvic pain, relugolix combination therapy achieved a clinically-meaningful reduction in 66.0% of women versus 42.6% women in the placebo group. On average, women receiving relugolix combination therapy had a 75.1% reduction on the 11-point Numerical Rating Scale for dysmenorrhea from 7.2 to 1.7. Six key secondary endpoints measured at Week 24 and compared to placebo achieved statistical significance, including changes in mean dysmenorrhea and overall pelvic pain, impact of pain on daily activities as measured by the Endometriosis Health Profile-30 pain domain, a greater proportion of women not using opioids, changes in non-menstrual pelvic pain, and dyspareunia. Relugolix combination therapy was generally well-tolerated with minimal bone mineral density loss over 24 weeks. The overall incidence of adverse events in the relugolix combination and placebo groups was similar. In the relugolix combination therapy group, 5.3% of women discontinued treatment early due to adverse events versus 3.9% in the placebo group. The most frequently reported adverse events, reported in at least 10% of women in the relugolix combination group, were headache, nasopharyngitis, and hot flashes. There were three pregnancies in the relugolix combination group and five in the placebo group. | |
---|---|---|
|
Earnings
|
Marvell sees Q1 adjusted EPS 23c-31c, consensus 27c »
16:06 03/03/21 03/0316:06 03/03/2116:06
MRVL
Marvell
Sees Q1 revenue $800M +/-… Story temporarily locked. ShowHide Related Items >><<
|
Hot Stocks
|
Provention Bio's teplizumab shows efficacy in delaying type 1 diabetes »
16:06 03/03/21 03/0316:06 03/03/2116:06
PRVB
Provention Bio
Provention Bio announced… Story temporarily locked. ShowHide Related Items >><<
|
Earnings
|
Splunk sees Q1 revenue $480M-$500M, consensus $507.29M »
16:06 03/03/21 03/0316:06 03/03/2116:06
SPLK
Splunk
Sees Q1 ARR… Story temporarily locked. ShowHide Related Items >><<
|
Earnings
|
Splunk reports Q4 EPS (86c) vs (15c) last year »
16:05 03/03/21 03/0316:05 03/03/2116:05
SPLK
Splunk
Reports Q4 revenue $745M,… Story temporarily locked. ShowHide Related Items >><<
|
Earnings
|
Marvell reports Q4 adjusted EPS 29c, consensus 29c »
16:05 03/03/21 03/0316:05 03/03/2116:05
MRVL
Marvell
Reports Q4 revenue $798M,… Story temporarily locked. ShowHide Related Items >><<
|
Earnings
|
Snowflake sees FY22 product revenue $1.00B-$1.02B, consensus $1.10B
16:04 03/03/21 03/0316:04 03/03/2116:04
SNOW
Snowflake
ShowHide Related Items >><<
|
Earnings
|
Snowflake sees Q1 product revenue revenue $195M-$200M, consensus $213.06M.
16:04 03/03/21 03/0316:04 03/03/2116:04
SNOW
Snowflake
ShowHide Related Items >><<
|
Hot Stocks
|
Okta to acquire Auth0 in deal valued at roughly $6.5B »
16:04 03/03/21 03/0316:04 03/03/2116:04
OKTA
Okta
Okta announced it has… Story temporarily locked. ShowHide Related Items >><<
|
Earnings
|
Descartes Systems reports Q4 EPS 20c, consensus 16c »
16:04 03/03/21 03/0316:04 03/03/2116:04
DSGX
Descartes Systems
Reports Q4 revenue… Story temporarily locked. ShowHide Related Items >><<
|
Syndicate
|
Tyler Technologies announces offering of convertible senior notes »
16:04 03/03/21 03/0316:04 03/03/2116:04
TYL
Tyler Technologies
Tyler Technologies… Story temporarily locked. ShowHide Related Items >><<
|
Earnings
|
Soleno Therapeutics reports Q4 EPS (4c), consensus (7c) »
16:03 03/03/21 03/0316:03 03/03/2116:03
SLNO
Soleno Therapeutics
The fair value of… Story temporarily locked. ShowHide Related Items >><<
|
Earnings
|
Snowflake reports Q4 EPS (70c), consensus (17c) »
16:03 03/03/21 03/0316:03 03/03/2116:03
SNOW
Snowflake
Reports Q4 revenue… Story temporarily locked. ShowHide Related Items >><<
|
Earnings
|
Okta sees FY22 adjusted EPS (49c)-(44c), consensus 1c »
16:03 03/03/21 03/0316:03 03/03/2116:03
OKTA
Okta
Sees FY22 revenue… Story temporarily locked. ShowHide Related Items >><<
|
Earnings
|
Okta sees Q1 adjusted EPS (21c)-(20c), consensus (7c) »
16:02 03/03/21 03/0316:02 03/03/2116:02
OKTA
Okta
Sees Q1 revenue… Story temporarily locked. ShowHide Related Items >><<
|
Earnings
|
Okta reports Q4 adjusted EPS 6c, consensus (1c) »
16:02 03/03/21 03/0316:02 03/03/2116:02
OKTA
Okta
Reports Q4 revenue… Story temporarily locked. ShowHide Related Items >><<
|
Hot Stocks
|
LivaNova up 3% after FT reports on Permira takeover bid
16:00 03/03/21 03/0316:00 03/03/2116:00
LIVN
LivaNova
ShowHide Related Items >><<
|
Periodicals
|
PE firm Permira has made bid to buy LivaNova, FT reports »
15:58 03/03/21 03/0315:58 03/03/2115:58
LIVN
LivaNova
Private equity group… Story temporarily locked. ShowHide Related Items >><<
|
Conference/Events
|
The Washington Association of Money Managers holds a virtual event »
15:55 03/03/21 03/0315:55 03/03/2115:55
IVZ
Invesco
David Wertheim, Portfolio… Story temporarily locked. ShowHide Related Items >><<
|
Syndicate
|
Alignment Healthcare files for IPO, applies to list on Nasdaq with symbol 'ALHC' »
15:53 03/03/21 03/0315:53 03/03/2115:53
ALHC
Alignment Healthcare
Alignment Healthcare has… Story temporarily locked. |
Options
|
Vroom options imply 20.7% move in share price post-earnings »
15:34 03/03/21 03/0315:34 03/03/2115:34
VRM
Vroom
Pre-earnings options… Story temporarily locked. ShowHide Related Items >><<
|
Recommendations
|
National Vision price target raised to $55 at Wells Fargo after Q4 results »
15:32 03/03/21 03/0315:32 03/03/2115:32
EYE
National Vision
Wells Fargo analyst… Story temporarily locked. ShowHide Related Items >><<
|
Recommendations
|
Wells Fargo lowers Wendy's target to $22 as current performance misses mark »
15:29 03/03/21 03/0315:29 03/03/2115:29
WEN
Wendy's
Wells Fargo analyst Jon… Story temporarily locked. ShowHide Related Items >><<
|
Recommendations
|
Michaels deal with Apollo Global 'a win for shareholders,' says Wells Fargo »
15:28 03/03/21 03/0315:28 03/03/2115:28
MIK
Michaels
Apollo Global
Wells Fargo analyst… Story temporarily locked. ShowHide Related Items >><<
|
Options
|
United Continental call volume above normal and directionally bullish »
15:25 03/03/21 03/0315:25 03/03/2115:25
UAL
United Airlines
Bullish option flow… Story temporarily locked. ShowHide Related Items >><<
|
Periodicals
|
Luminex jumps 8% after Bloomberg says company exploring sale »
15:22 03/03/21 03/0315:22 03/03/2115:22
LMNX
Luminex
DiaSorin SpA
Bloomberg, which… Story temporarily locked. ShowHide Related Items >><<
|